Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc    MYL   US6285301072


SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

04/30/2012 | 02:20pm US/Eastern

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit For more information about generic drugs, please visit

SOURCE Mylan Inc.

Recommend :
React to this article
Latest news on MYLAN INC
5d ago MYLAN : Patent Issued for Stabilized Tolterodine Tartrate Formulations
5d ago MYLAN : To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Gen..
5d ago MYLAN : Wins Motion to Enjoin GlaxoSmithKline from Providing Paroxetine CR to Ap..
5d ago MYLAN : Wins Motion for Temporary Restraining Order Against Apotex for Authorize..
6d ago EXCLUSIVE - INDIA'S LUPIN, U.S. FIRM : sources
6d ago India's Lupin, U.S. firms weigh bids for GSK's mature drugs -sources
07/19DJRoche Not Interested in Large Acquisitions, Says CEO -- Report
07/18 MYLAN : More Tax Inversions: Abbott Selling Part of Generic Drug Business to Myl..
07/17 MYLAN : Says It Wins Motion To Enjoin GSK From Providing Paroxetine CR To Apotex
07/17 MYLAN : Wins Motion to Enjoin GlaxoSmithKline from Providing Paroxetine CR to Ap..
Dynamic quotes